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The low-density lipoprotein receptor-related protein
(LRP1B), encoding an endocytic LDL-family receptor,
is among the 10 most significantly deleted genes across
3312 human cancer specimens. However, currently the
apparently crucial role of this lipoprotein receptor in
carcinogenesis is not clear. Here we show that LRP1B
inactivation (by chromosomal, epigenetic and microRNA
(miR)-mediated mechanisms) results in changes to the
tumor environment that confer cancer cells an increased
growth and invasive capacity. LRP1B displays frequent
DNA copy number loss and CpG island methylation,
resulting in mRNA underexpression. By using CpG
island reporters methylated in vitro, we found that DNA
methylation disrupts a functional binding site for
the histone-acetyltransferase p300 located at intron 1.
We identified and validated an miR targeting LRP1B
(miR-548a-5p), which is overexpressed in cancer cell lines
as a result of 8q22 DNA gains. Restoration of LRP1B
impaired in vitro and in vivo tumor growth, inhibited cell
invasion and led to a reduction of matrix metalloprotei-
nase 2 in the extracellular medium. We emphasized the
role of an endocytic receptor acting as a tumor suppressor
by modulating the extracellular environment composition
in a way that constrains the invasive behavior of the
cancer cells.
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Introduction
The low-density lipoprotein receptor-related protein
gene (LRP1B) originally isolated on the basis of
homozygous deletions detected in human lung cancer
cell lines (Liu et al., 2000a, 2000b; Kohno et al., 2010)
was recently reported among the top 10 most signifi-
cantly deleted genes across 3312 human cancer speci-
mens (Beroukhim et al., 2010). LRP1B encodes for a
member of the endocytic low-density lipoprotein recep-
tor superfamily. The classical role of LRPs is to mediate
the clearance of a myriad of extracellular ligands from
the pericellular environment (Herz and Strickland, 2001;
May et al., 2007). Among these ligands are lipoprotein
complexes, trimeric complexes of urokinase plasmino-
gen activator (uPA), plasminogen activator inhibitor
type 1 and uPA receptor (Herz et al., 1992; Nykjaer
et al., 1992), as well as matrix metalloproteinases
(MMPs) (Emonard et al., 2005). LRP1B is most highly
expressed in the brain and thyroid gland (Liu et al.,
2001; Asami et al., 2009), and a susceptibility locus for
familial non-medullary thyroid cancer (fNMTC) at 2q21
(McKay et al., 2001), encompassing LRP1B, as well
as loss of heterozygosity at 2q21 has been detected
in familial (Prazeres et al., 2008) and sporadic non-
medullary thyroid cancer (NMTC) (Stankov et al.,
2004). For these reasons, we undertook the present
study to elucidate the mechanisms of LRP1B inactiva-
tion in cancer cells and to investigate the key roles of this
lipoprotein receptor in the carcinogenesis of familial and
sporadic thyroid tumors.
Results
Global gene expression profile of familial and sporadic
NMTC tumors filters LRP1B as the only significant
deregulated gene at 2q21
LRP1B first came to our attention in the study of
the individual tumors of an fNMTC family mem-
ber with a presumable 2q21 susceptibility haplotype
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(Supplementary Figure S1A). We performed gene
expression profiling in the only tumor (out of four)
without loss of heterozygosity at 2q21 by using Affymetrix
U133A Plus 2.0 Genechips (Affymetrix, Santa Clara,
CA, USA). Among the probesets which encompass the
2q21 region (4200 probesets; 64 candidate genes,
Supplementary Table S1), LRP1B was the only gene
found to be deregulated. In complement, analysis
of 2q21 probesets was done in the data set derived
from expression profiling (Affymetrix Human Exon 1.0
ST Array, Affymetrix) of a validation series comprising
sporadic thyroid tumors (12 normal samples, 12 follicular
thyroid adenomas (FTA) and 18 follicular thyroid
carcinomas). Concordantly, we found that LRP1B was
the single probeset in 2q21 region showing significant
deregulation (threefold cutoff) in sporadic tumors (Sup-
plementary Table S2). Quantitative real-time–PCR (qRT–
PCR) was used to validate the results obtained with the
microarrays. LRP1B was shown to be downregulated to
similar levels in the two fNMTC samples when assessed
by complementary (c)DNA microarray or qRT–PCR
(12.15 and 10.1, respectively, Figure 1a). Further-
more, LRP1B was completely silenced or downregulated
to variable levels in all the thyroid cancer cell lines
analyzed (Figure 1a), suggesting that LRP1B might be
relevant in the carcinogenesis of both familial and also
sporadic thyroid cancer. We sequenced, in the index
family member, the 16 kbp of the entire coding sequence
(91 exons) and flanking intron boundaries of LRP1B, as
well as cDNA fragments encompassing several exons.
Aside from previously reported single-nucleotide poly-
morphisms and intronic variants of unknown significance
(Supplementary Figure S1B), we were unable to detect any
causative germline mutation in the fNMTC case studied.
We additionally screened for mutations in five sporadic
thyroid tumor DNAs. In one sporadic non-medullary
thyroid cancer, we could demonstrate a frameshift
deletion: del68_146 at the transcript level (nucleotide þ 1
is the ATG initiation codon), which is predicted to
translate a truncated LRP1B protein (Figure 1b).
Genomic loss of LRP1B is frequent in sporadic thyroid
tumors
As LRP1B was initially identified by the observation of
homozygous deletion in lung cancer cell lines, which led
to the initial designation of LRP-DIT—a gene found to
be deleted in tumors, we were prompted to investigate
whether LRP1B is subjected to genomic loss. For this
purpose, we used genomic qRT–PCR assays directed
at LRP1B sequences in the upstream, middle and
downstream parts of the gene (exons 5, 44 and 90,
respectively), as well as sequences near the chromosome
2 centromere. We found that LRP1B frequently displays
genomic loss both in cell lines (5/10, Figure 2a) and also
in sporadic tumors (13/20 FTAs, 13/15 follicular thyroid
carcinomas (FTCs), 14/19 papillary thyroid carcinomas
(PTCs) and 6/10 undifferentiated thyroid carcinomas
(UTCs); Figure 2b). In most cases, losses at LRP1B are
accompanied by loss at the centromeric locus, indicating
that probably the entire chromosomal arm was deleted
(Figure 2b). We could observe cases in which copy
number values dropped in internal exons of LRP1B,
indicating that the deletion breakpoints were intragenic
(for example, PTC-14). We could also detect cases with
a presumable homozygous loss, displaying a calculated
copy number value close to zero (Figure 2b).
LRP1B underexpression follows thyroid cancer
progression and correlates with vascular invasion
We analyzed the expression levels of LRP1B at the
mRNA level. In accordance with the results observed in
thyroid cancer cell lines, we found underexpression at
variable degrees, both in pre-malign lesions, such as
FTA, as well as in carcinomas, such as FTC, PTC and
UTC (Figure 3a). The only case of UTC displaying
normal LRP1B mRNA expression was shown to harbor
the above-mentioned somatic frameshift mutation
(Figure 1B). Noteworthy, the expression level of LRP1B
was significantly lower in thyroid lesions, compared with
normal thyroid tissue (Po0.02), and the expression in
UTCs was significantly lower than in differentiated
thyroid cancers (P¼ 0.036, Figure 3b). The levels of
LRP1B were significantly lower in cases with vascular
invasion compared with cases without vascular invasion,
namely in FTC (P¼ 0.04, Figure 3c). A statistically
significant underexpression of LRP1B was reproduced
in the validation set comprising 12 FTAs and 18 FTCs
compared against 12 normal thyroid samples (P¼ 0.03,
Figure 3d). This was further confirmed in cases in which
paired normal and tumor specimens were available
Figure 1 LRP1B is silenced in fNMTC tumors and in thyroid
cancer cell lines and is subjected to genetic mutation in a sporadic
NMTC. (a) mRNA expression of LRP1B in thyroid cancer cell
lines, normal thyroid and tumors derived from the index fNMTC
case (fNMTC-tumor1 and fNMTC-tumor2). Expression values
were normalized to the endogenous control and divided by the
relative expression of the normal thyroid sample. (b) Sequencing
chromatogram, illustrating a LRP1B deletion mutation encom-
passing exon 1 to exon 2 (del68_146 at the transcript level) detected
in one out of five sporadic NMTCs scanned for LRP1B mutations.
The arrow indicates the deletion site after which an overlap of the
wild-type and deleted alleles is observed.
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(P¼ 0.015, Figure 3e). However, the association with
vascular invasion was not statistically significant in the
validation series.
DNA methylation disrupts a transcription factor binding
site for p300 at LRP1B intron 1
We asked whether DNA methylation or other epi-
genetic factors allowed explanation for the observed
transcriptional downregulation of LRP1B. By bisulfite
sequencing two fragments of the LRP1B CpG island,
we detected DNA methylation in 6/10 cell lines and in
10/19 FTAs, 9/16 FTCs, 11/17 PTCs and 5/7 UTCs
(Figure 4a). No methylation was observed in any of the
normal thyroid samples, confirming that the observed
methylation is tumor-specific and excluding the
possibility that the observe methylation constitutes
tissue-specific methylation (Figure 4a). The pattern
Figure 2 Genomic loss of LRP1B is frequently found in thyroid cancer cell lines and sporadic thyroid tumors. LRP1B DNA copy
number in 10 thyroid cancer cell lines (a) and thyroid lesions (20 FTAs, 15 FTCs, 19 PTCs and 10 UTCs) (b) was determined by
genomic quantitative real-time PCR employing primer/probe pairs targeting different genetic regions of LRP1B, namely exon 5, 44 and
90 (CN_LRP1B_X5; _X44 and_X90) and at a region near the 2q centromere (CN_2q). The abundance of DNA copies at each site was
normalized to an endogenous control for RNAse P run in multiplex reactions and copy number values were calibrated by performing
reactions with blood-derived DNA sample in the same plate. Data were generated with the CopyCaller software.
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Figure 3 LRP1B underexpression follows thyroid cancer progression and correlates with vascular invasion. (a) Real-time PCR
quantification of the LRP1B transcript in mRNA samples derived from micro-dissected thyroid lesions. Expression values were
normalized to an endogenous control (hPO) and a normal reference (a pool of nine mRNAs obtained from normal thyroid samples
subjected to the same treatment as the other cases) was quantified in triplicate in the same plate. (b) Differences in the relative expression
ratios for each histotype of thyroid lesions are displayed in box-plot graphics. LRP1B is significantly underexpressed in thyroid tumors
relative to normal thyroid, and in UTC versus differentiated thyroid tumors (FTC and PTC). In the graphics, open circle (J) or
asterisk (*) refer to the outlier cases. Statistical significance P-values were obtained by using the Mann–Whitney test. (c) LRP1B mRNA
levels are significantly lower in FTCs with vascular invasion. (d) In a validation series gathered by an independent group and analyzed
by a different method (exon arrays), LRP1B is reproducibly found to be underexpressed in tumor versus normal thyroid tissue. (e) This
observation is further confirmed when paired normal and tumor material was analyzed.
LRP1B inactivation modulates the extracellular microenvironment
H Prazeres et al
1305
Oncogene























































































Partially methylated at CpG
Methylation at Non-CpG


















LRP1B inactivation modulates the extracellular microenvironment
H Prazeres et al
1306
Oncogene
of methylation was heterogeneous, without evidence
of preferential methylation of a particular CpG
(Figure 4a). However, our attention was caught by the
observation of methylation in both CpG and non-CpG
sites (Figure 4b, inset). The prevailing assumption is that
DNA methylation in the mammalian genome is
restricted to CpGs. Nonetheless, evidence for a class of
non-CpG methylation in mammalian cells comes from
several previous studies (Toth et al., 1990; Clark et al.,
1995; Woodcock et al., 1997; Malone et al., 2001), and
recently it was reported in the first complete sequence of
the human DNA methylome (Lister et al., 2009) that
non-CpG sites comprised as much as 25% of methylated
cytosines in a human embryonic stem cell line. A funda-
mental question raised by these results was regarding the
functional significance of apparently stochastic methyla-
tion in CpG and non-CpG contexts. Analysis of all the
sites found to be methylated in non-CpGs in cell lines
and tumors indicated that 1/3 of all sites occur in the
sequence *CCGG, with methylation of the external C.
To address this question, CpG island luciferase repor-
ters with two fragments of the promoter region
were generated (fragments A and B). We differentially
methylated CpG island luciferase reporters by in vitro
methylation with bacterial methyltransferases M.Sss-I
(*CG), M.Msp-I (*CCGG) and M.Hpa-II (C*CGG)
(Figure 5a, chromatograms in Supplementary Figure
S2). We found luciferase activity to be increased by the
unmethylated fragments of the CpG island (Figure 5a).
As expected, complete M.Sss-I-mediated methylation of
all *CpGs resulted in abrogation of luciferase activity to
values similar to the empty vector. Interestingly, low-
density methylation induced by M.Msp-I and M.Hpa-II
impaired the transcriptional activity of the reporter-
containing fragment B of the CpG island, but not the
fragment A reporter (Figure 5a). We reasoned that
DNA methylation might interfere with the binding of
putative transcription factors to the specific sequences
flanking CCGG in fragment B. Using TFSEARCH 1.3
(Heinemeyer et al., 1998), we found that a binding motif
for the p300 histone-acetyltransferase (GGGAGTG)
(Rikitake and Moran, 1992) was present immediately
upstream of one of the M.Msp-I/M.Hpa-II CCGG sites
(CCGGGAGTG). These observations led us to inves-
tigate whether p300 activates the expression of LRP1B
and if this effect is methylation sensitive. For this
purpose, we transfected HEK293 cells with unmethy-
lated or methylated luciferase constructs of fragment B,
either with or without the addition of a p300 expression
vector. We found that addition of p300 increased the
luciferase activity of the unmethylated construct. How-
ever, the p300 enhancer effect was abrogated when
either M.Msp-I or M.Hpa-II methylated versions of
the reporter were used (Figure 5b). In order to confirm
the direct binding of p300 to this LRP1B sequence and
its possible perturbation by DNA methylation, we
performed proximity ligation assay (Gustafsdottir
et al., 2007) using DNA probes in the unmethylated,
methylated and mutated forms. We showed a 64-fold
increase in interactions between p300 and a DNA
probe composed of the LRP1B intron 1 unmethylated
sequence as compared with probes with a mutated
binding site or with methylated *CG and *CCG sites
(Figure 5c). In complement to this, we transfected
HEK293 and C643 cells with a small interfering RNA
designed to inhibit the endogenous p300 and could
demonstrate a concomitant reduction in LRP1B expres-
sion (Figure 5d). Overall, these results indicate that there
is a functional p300 binding site at intron 1 of LRP1B,
which could be disrupted by DNA methylation of the
flanking CCG sequence. Moreover, these findings high-
light the possibility that methylation at unique cytosines,
even in a stochastic or non-CpG context, may affect gene
transcription, by interfering with cis regulatory elements.
Finally, because our findings highlight a role for
DNA methylation and histone acetylation in regulation
of LRP1B expression, we decided to check whether the
use of a DNA-demethylating agent, 5-Aza-20-deoxycy-
tidine (5AZA), or a histone deacetylase inhibitor,
Trichostatin A (TSA), could restore the expression of
LRP1B mRNA in vitro. In cell lines ARO and XTC-1,
in which we previously demonstrated LRP1B promoter
DNA methylation (Figure 4a), we could show that
LRP1B is re-expressed by use of 5AZA or TSA either
alone (ARO) or in combination (XTC-1) (Figure 5e).
Overexpression of miR-548a-5p caused by genomic gain
at 8q22.3 leads to LRP1B downregulation
Despite the generalized silencing of LRP1B, only three
cell lines displayed widespread DNA methylation, and
although p300 levels were downregulated in cell lines,
they do not appear to account for the differences in
the degree of LRP1B downregulation (Supplemen-
tary Figure S3). MicroRNAs (miRs) have emerged
as alternative mediators of tumor suppressor gene
inactivation (Nagel et al., 2008) by means of inhibition
of translation and/or reducing mRNA stability. We
investigated whether overexpression of putative miRs
that target LRP1B could be an additional mechanism
of LRP1B inactivation. To this end, we started by
computationally nominating potential miRs that may
target the LRP1B 30UTR and 50UTR using the
MirBase, TargetScan and MicroInspector prediction
Figure 4 DNA methylation at the LRP1B CpG island disrupts a transcription factor binding site for p300 at intron 1. (a) Profile of
DNA methylation of the LRP1B CpG island in thyroid cancer cell lines, normal thyroid samples and thyroid tumors. Methylation
analysis was performed by bisulfite-PCR-sequencing of two independent fragments of the CpG island (fragment 1: 131 to þ 100 and
fragment 2: þ 217 to þ 365, counting from ATG) in 10 thyroid cancer cell lines and in 19 FTAs, 16 FTCs, 17 PTCs and 7 UTCs.
Methylation status was also assessed in 24 samples of normal thyroid tissue. Circles represent CpG and non-CpG sites in different
configurations: J—un-methylated; —fully methylated; —partially methylated; —fully methylated in a non-CpG site and
—partial methylation at a non-CpG. (b) This inset contains bisulfite-sequencing chromatograms illustrating sites of non-CpG
methylation; H stands for C; A or T.
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tools. We selected 12 miRs by this in silico analysis
(miR-155, 200b, 429, 548a, 548b, 548d, 520d,
524, 142, 7, 497 and miR-103). We quantified the
expression of the 12 selected miRs in the 10 thyroid
cancer cell lines available (see Supplementary Figure S4)
and looked for miRs with an expression level that
inversely correlated with LRP1B expression. By per-
forming this sort of analysis, we could observe that
overexpression of miR-548a-5p strikingly paralleled the
decrease in LRP1B expression, with exception of the cell
lines that previously demonstrated high levels of prom-
oter methylation (ARO, KAT4 and XTC-1) (Figure 6a).
This association was also observed in vivo in samples
from the index fNMTC case. The miR-548a-5p binding
site at LRP1B 30UTR is conserved across six species,
comprising primates, mice and chicken, and shows
considerable sequence complementarity at the miR seed
region (9-mers) (Figure 6b). Next, we proceeded to
functionally validate that LRP1B is targeted by miR-
548a-5p for downregulation. To examine whether miR-
548a-5p binds to the 3UTR of LRP1B, we generated
luciferase reporters encoding the wild-type and mutated
versions of the LRP1B 30UTR. We transfected HEK293
cells with an expression plasmid encoding the precursor
transcript of miR-548a-5p (PremiR-548a-5p) and ob-
served that overexpression of miR-548a-5p decreased
the activity of the LRP1B 30UTR luciferase reporter
(Figure 6c). This effect was abrogated in the mutant
LRP1B 30UTR reporter, in which the binding site of
miR-548a-5p was mutated (Figure 6c). To further
support the relationship between LRP1B and miR-
548a-5p, we employed anti-miR sequences to specifically
inhibit miR-548a-5p expression in a cell line previously
shown to have miR-548a-5p overexpression and
very low levels of LRP1B (TPC-1). We verified that
treatment with anti-miR-548a-5p, but not a scramble
control, resulted in the increase of endogenous LRP1B
mRNA levels (Figure 6d). miR-548a-5p is derived from
processing of a pri-miR intergenic transcript, encoded
by a minute inverted repeat transposable element, which
maps to 8q22.3. Interestingly, 8q gains were one of
the most frequent cytogenetic abnormalities in thyroid
cancer cell lines (Ribeiro et al., 2008) and 8q22 amplifi-
cation is a recurrent finding in several solid malignan-
cies and may subclassify breast cancer patients with
poor prognosis (Chin et al., 2007; Walker et al., 2008;
Horlings et al., 2010). However, miRs in this location
were always disregarded in surveys for genes upregu-
lated in this amplified region. In the interest of exploring
the hypothesis that DNA gains could be the key
underlying mechanism of miR-548a-5p overexpression,
we employed TaqMan Copy number assays (Applied
Biosystems, Carlsbad, CA, USA) to ascertain DNA
copy number at the miR-548a-5p locus (8q22.3). We
found that 6/10 cell lines display copy number gains,
whereas two cell lines display copy number loss
(Figure 6e). Copy number gains at 8q22.3 are signifi-
cantly correlated with miRNA-548a-3 overexpression
(Figure 6f). These findings provide evidence for a novel
mechanism of LRP1B inactivation, alternative to DNA
methylation, acting through 8q22.3 genomic gain, miR-
548a-5p overexpression and direct targeting of LRP1B.
Integration of these ‘hits’ indicates that LRP1B inacti-
vation may arise through diverse sequence of events
during carcinogenesis (see Supplementary Table S3).
Restoration of LRP1B inhibits in vitro and in vivo
growth, and impairs matrigel cell invasion
The role of LRP1B as a tumor suppressor is poorly
studied. In keeping with the hypothesis that LRP1B acts
as a tumor suppressor gene, we looked for a reversal of
the malignant phenotype upon restoration of LRP1B.
XTC-1 cells stably transfected with either a mini-
receptor form of LRP1B (mLRP1B), which mimics the
function and trafficking of LRP1B (Liu et al., 2001), or
an empty vector were used in soft agar growth assays.
We found that XTC-1 cells stably expressing mLRP1B
gave rise to a significantly lower number of colonies as
compared with cells selected with an empty vector
(Po0.05, Figures 7a and b). To examine the effect of
LRP1B in tumor growth in vivo, CHO cells, which are
null for endogenous LRP1B, were stably transfected with
either mLRP1B or empty vector and were inoculated into
chicken chorioallantoic membrane. Six days after inocula-
tion, all embryos developed tumors. However, tumors
derived from mLRP1B-expressing cells were significantly
smaller (P¼ 0.002) than tumors derived from CHO
cells transfected with the empty vector (Figures 7c and
d). In order to determine the role of LRP1B in cancer cell
Figure 5 DNA methylation at a specific site of intron 1 of LRP1B disrupts binding and transcription enhancement mediated by p300.
(a) Luciferase activity derived from transfection of HEK293 cells with pTAL-LUC reporter constructs containing independent
fragments of the LRP1B CpG island (fragment A: 429 to 1 and fragment B: þ 1 to þ 530, counting from ATG), each subjected to
in vitromethylation using M.Sss-I, M.Msp-I or M.Hpa-II (with *CG, *CCGG and C*CGGmethylation specificities, respectively) as is
represented schematically. (b) In the second experiment, luciferase activity of unmethylated and M.Hpa-II methylated constructs was
measured in either the presence or the absence of a p300 expression vector co-transfected along with the reporters. (c) Proximity
ligation real-time PCR quantification of the interactions between p300 and DNA probes consisting of the putative LRP1B p300 motif
sequence in wild-type (WT), mutated (MUT) and methylated (C*CG and C*CG) configurations. The inset displays real-time PCR
amplification curves. Results were expressed as signal/noise ratio, where the number of ligations in the sample was divided by the
number of ligations in the negative control. (d) Expression of endogenous LRP1B upon inhibition of endogenous p300 by small
interfering RNA (siRNA). HEK293 and C643 cells were transfected with a scramble siRNA control (siCont) or with a siRNA for p300
(sip300) and the effect on LRP1B expression was quantified by real-time PCR. The insets show concomitant underexpression of p300
in the same samples. The graphs integrate data from three experiments. (e) Analysis of LRP1B mRNA expression upon treatment of
ARO and XTC-1 cell lines (displaying LRP1B CpG island DNA methylation) with 5AZA, TSA or both (5AZAþTSA). Non-treated
cells (NT) or cells treated with dimethyl sulfoxide solvent were used as controls.
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invasion, we performed in vitro matrigel invasion assays
employing the otherwise highly invasive UTC cell line
8505C, in which mLRP1B was stably introduced. We
observed a significant inhibition of invasive capacity of
8505C stably expressing mLRP1B relative to cells selected
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LRP1B leads to overall changes in the extracellular
microenvironment
Working under the hypothesis that through its endocy-
tic activity LRP1B might modulate the amount of
soluble factors in the tumor microenvironment, we
decided to investigate the impact of LRP1B in the
extracellular medium. For this purpose, we used
membrane-based cytokine antibody arrays to compare
the levels of 51 ytokines (Supplementary Figure S5A) in
the conditioned medium of 8505C cells transfected with
mLRP1B, relative to cells selected with empty vector.
We found overall changes in the amounts of several
cytokines quantified by this method (Supplementary
Figures S5B–D). The most prominently altered mole-
cules were Ferritin, TACE, TRAILR2, NRG1-beta1,
NrCAM, TREM1 and XEDAR, all found to be reduced
in the media of mLRP1B-expressing cells (Supplemen-
tary Figures S5C and D). Furthermore, several MMPs
were found to be weakly reduced in mLRP1B 8505C
cells. Nevertheless, the antibody employed in the array
does not discriminate between the active and inactive
form of MMPs. To clear the relation between LRP1B
and MMPs, we performed gelatin zymography with the
conditioned medium of 8505C cells. The cells were
plated onto fibronectin-coated plates so as to stimulate
the expression of MMPs. We found that the levels of
matrix metalloproteinase 2, mainly the latent form, but
not MMP9 or MMP1 (latent or active), were signifi-
cantly reduced in the conditioned medium of mLRP1B-
expressing cells (Figure 7f). We confirmed that this
difference was not attributable to different levels of
matrix metalloproteinase 2 mRNA in 8505C-empty and
8505C-mLRP1B cells, as settled by qRT–PCR quanti-
fication (Figure 7f inset).
Discussion
Overall, the present work led to the identification of
an otherwise unexpected mechanistic link between
chromosomal changes (at 2q21 and 8q22.3), an epi-
genetic transcription factor (p300) and a specific miR
(miR-548a-5p) in (de)regulation of LRP1B, which in
turn restrains cancer cell growth and invasion by
modulating the extracellular medium (Figure 8).
In the start of this study, LRP1B came to our
attention because it was shown to be the only gene
significantly targeted for downregulation within the
2q21 susceptibility locus, both in familial and in sporadic
NMTC. Despite the lack of finding a causative germline
mutation in the index family, at this point we cannot
exclude LRP1B as a candidate gene for fNMTC.
However, we do not disregard some weaknesses that
might have arisen from our strategy. In one hand, the
small size of the index family (a common feature in
fNMTC) did not allow ascertainment of linkage to
2q21. Despite a high probability of a susceptibility locus
at 2q21 existing on the basis of the pattern of allelic
losses, focus on 2q21 without definitive evidence of
linkage may have misled our search from alternative
fNMTC loci reported at 14q (Bignell et al., 1997), 1q21
(Malchoff et al., 2000), 19p13.2 (Canzian et al., 1998),
8p23 (Cavaco et al., 2008), 8q24 (He et al., 2009), 1q21
and 6q22 (Suh et al., 2009). On the other hand, because
the LRP1B coding sequence is 16 kbp long and consists
of 91 exons, it was not feasible to perform exhaustive
mutation screening in a larger set of samples. We are
undertaking further sequencing efforts employing gen-
ome sequencing technology in a larger number of
families linked to 2q21 in order to clear this issue.
Nevertheless, we were able to demonstrate somatic
mutation and frequent genomic deletions involving
LRP1B in sporadic non-medullary thyroid cancer,
which, aside from thyroid cancer, are observed across
various cancer types, namely in the lung, esophagus,
breast, hepatocellular, renal, neural and colorectal
cancer (http://www.broadinstitute.org/tumorscape/pages/
portalHome.jsf).
Aside from structural alterations, we showed tran-
scriptional silencing of LRP1B due to DNA methyla-
tion, disrupting a previously undisclosed functional
Figure 6 Overexpression of miR-548a-5p leads to LRP1B downregulation. (a) Correlation between miR-548a-5p expression and
LRP1B mRNA levels in thyroid cancer cell lines, normal and tumor material from the index case (normal thyroid, fNMTC-tumor1
and fNMTC-tumor2). Alignment of the two graphics illustrates the tight inverse correlation between miR-548a-5p and LRP1B, which
is observed both in cell lines and in vivo (fNMTC-tumor1 and -tumor2 samples). In cell lines ARO and KAT4, LRP1B is highly
downregulated without simultaneous miR-548a-5p overexpression, which is probably the result of previously demonstrated alternative
inactivation events such as copy number loss and complete promoter hypermethylation (Supplementary Table S3). The inverse
correlation between miR-548a-5p and LRP1B was demonstrated by an X/Y plot with a significant Pearson correlation
(ARO and KAT4 were excluded from this analysis). (b) Degree of sequence complementarity between miR-548a-5p seed region
and its cognate binding site at the LRP1B 30UTR (9-mers). This site is conserved among primate species, mice and chicken.
(c) Luciferase activity was assayed in HEK293 cells co-transfected with a miR-548a-5p expression vector (pEPmir-548a-3) along with
either a pMIR-REPORT construct containing the wild-type 30UTR of LRP1B (pMIR-REPORT-LRP1B-30-Wt) or a 30UTR sequence
in which two nucleotides of the miR-548a-5p seed region were mutated (pMIR-REPORT-LRP1B-3’-Mut). (d) Endogenous expression
of LRP1B upon 16h treatment of TPC-1 cells with anti-miR-548a-5p RNAs in two concentrations: 25 nM and 50 nM. A scramble
control siRNA (siCont) and mock (MOK) conditions were used as controls. The inset shows concomitant underexpression of miR-
548a-5p in the same samples. The graph integrates data from three experiments. (e) Analysis of miR-548a-3 DNA copy number in
thyroid cancer cell lines determined by genomic quantitative real-time PCR employing primer/probe pairs targeting genetic regions
immediately upstream and downstream of the miR-548a-5p genomic locus (CN_50 of miR-548a-3 and CN_3’of miR-548a-3) as well as
at a region near the 8q centromere (CN_8q). The abundance of DNA copies at each site was normalized to an endogenous control for
RNAse P run in multiplex reactions and copy number values were calibrated by performing reactions with blood-derived DNA sample
in the same plate. Data were generated with the CopyCaller software. (f) Correlation between DNA copy number at the miR-548a-5p
locus and miR-548a-5p expression.
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Figure 7 LRP1B inhibits in vitro and in vivo tumor growth, impairs in vitro cell invasion and leads to a reduction of matrix
metalloproteinase 2 (MMP2) in the extracellular medium. (a) Soft agar growth was measured in XTC-1 cells stably selected with either
an expression vector encoding a LRP1B mini-receptor, which mimics the function and trafficking of LRP1B (mLRP1B), or an empty
vector control (empty vector). The XTC-1 cell line was chosen on the basis that it forms agar colonies and because endogenous LRP1B
mRNA was greatly impaired. Stable clones were pooled and 5000 cells per well were mixed with soft agar in appropriate medium and
plated in six-well plates previously coated with a bottom layer of agar. (b) After 2 weeks in the incubator, colonies were stained with
crystal violet, photographed and counted. (c) In vivo chicken embryo growth assay was performed using CHO cells stably transfected
with either mLRP1B or empty vector control. A total of 2 106 cells were inoculated into the chorioallantoic membrane and allowed to
grow for 6 days. The resulting tumors were photographed. (d) Ex ovo images were used to determine the areas of the tumors and
produce a box plot, which integrates data from seven different inoculations of each condition. The Wilcoxon rank sum test was used to
calculate statistical significance. (e) In vitro cell invasion assayed by matrigel invasion chambers in 8505C cells stably transfected with
mLRP1B or empty vector control. A total of 2.5 104 cells were plated in 24-well plates with filter inserts containing a polyethylene
terephthalate membrane of 8 mm size pores occluded by a thin layer of matrigel basement membrane matrix. After 24 h, the invasive
cells that were able to invade into the lower surface of the filter were fixed, stained with DAPI and counted under the microscope. The
graph contains data from three experiments. (f) Conditioned medium was obtained from stable 8505C mLRP1B or 8505C empty
vector control cells by placing 2.5 105 cells in fibronectin-coated six-well plates for 24 h in 1ml serum-free media. Three wells were
seeded for each condition (triplicates). For gelatin zymography, 20 ml of the same conditioned medium was separated in a non-reducing
PAGE gel containing 1mg/ml gelatin. After MMP activation, gels were stained with Coomassie blue to allow the visualization of
gelatinolytic bands. This experiment was performed twice and a representative gel is presented. Recombinant MMP2 was used as a
control. Low-molecular-weight bands in the control were generated by MMP2 autolysis.
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p300 binding site at intron 1 of LRP1B. The EP300 gene
encodes p300, a histone-acetyltransferase that regulates
transcription via chromatin remodeling, and is impor-
tant in the processes of cell proliferation and differ-
entiation (Gayther et al., 2000). A role for p300 in
cancer has been previously implied by the fact that it is
targeted by viral oncoproteins (Arany et al., 1995), it is
fused to myeloid lymphoblastic leukemia in leukemia
(Ida et al., 1997) and mutations in EP300 were described
in epithelial malignancies with inactivation of the second
allele (Muraoka et al., 1996; Gayther et al., 2000). Our
results are of significance as they place LRP1B in the
p300 suppressor pathway.
In this work, we have noticed that genomic gain at
8q22.3 goes together with miR-548a-5p overexpression,
which in turn directly targets LRP1B for downregula-
tion, resulting in increased invasive capacity. Chromo-
some 8q22 amplification has been repeatedly associated
with poor patient outcome in other cancer models,
particularly in breast cancer (Chin et al., 2007; Walker
et al., 2008; Horlings et al., 2010). It remains to be seen
whether poor patient outcome is due to the workings of
this newly identified circuitry.
At some point in epithelial tumor progression, cancer
cells overcome the basement membrane and acquire the
means to invade through the interstitial connective
tissue. These properties are partly conferred by activat-
ing proteolysis systems, which promote extracellular
matrix degradation such as the uPA (Ulisse et al., 2009)
and MMPs (Roy et al., 2009). Aside from modulating
matrix metalloproteinase 2, as shown here, LRP1B has
also been reported to regulate the uPA system (Liu
et al., 2001). Cells expressing LRP1B display a
substantially slower rate of uPA/plasminogen activator
inhibitor type-1 complex internalization (Knisely et al.,
2007), which impairs the regeneration of unoccupied
urokinase plasminogen activator receptor on the cell
surface and correlates with a diminished rate of cell
migration (Li et al., 2002; Tanaga et al., 2004). Our
results highlight LRP1B as an unconventional and yet
key tumor suppressor acting as a regulator of the
‘extracellular proteome’ and constraining the abundance
of critical members of proteolytic systems in the tumor
microenvironment. These functions may be overlapping
and yet distinct from other LDL receptor family
members (Liu et al., 2001). The closest related member,
LRP1, shows controversial effects on MMP catabolism
and cell invasion, which seem to be dependent on the cell
context (Hahn-Dantona et al., 2001; Yang et al., 2001;
Emonard et al., 2004; Desrosiers et al., 2006; Dedieu
et al., 2008; Song et al., 2009).
As the extracellular domain of LRP1B may poten-
tially bind to a myriad of still undisclosed ligands
(Marschang et al., 2004), it is possible that the tumor sup-
pressor properties of this receptor are further explained
by modulation of the extracellular concentration of
other molecules critical for tumor progression, secreted
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Figure 8 Schematic representation of chromosomal, epigenetic and microRNA-mediated changes leading to LRP1B (de)regu-
lation, which, in turn, restrains cancer cell growth and invasion by mediating clearance of matrix metalloproteinase 2 from the
extracellular medium.
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It is also conceivable that additional tumor suppressor
functions of LRP1B are mediated by signaling pathways
elicited by its intracellular domain (Liu et al., 2007;
Shiroshima et al., 2009).
Our findings give scope for the use of LRP1B activity
as a tool for a therapeutic approach that is not centered
on the cancer cell itself, but rather in its environment,
aiming to control the invasive behavior of the cancer
cell by modulating the composition of the environment
surrounding it. This may have repercussions to some
of the most prevalent cancer types in which LRP1B is
also found to be silenced (Supplementary Figure S6). A
future challenge will be to use the newly identified
LRP1B (de)regulatory mechanisms to design the strat-
egy for such intervention.
Materials and methods
Familial subjects
The index fNMTC family studied was reported elsewhere
(Prazeres et al., 2008) and the pedigree is depicted in
Supplementary Figure S1A.
Sporadic cases
The testing series consisted of 71 formalin-fixed, paraffin-
embedded tissue samples, comprising 20 FTAs, 17 FTCs, 24
PTCs and 10 undifferentiated thyroid carcinomas (UTCs). We
also studied 24 samples of normal thyroid tissue dissected from
specimens obtained from total thyroidectomies.
Cell lines and transfections
We used 10 cell lines, HTH74, C643, NPA, K1, BCPAP,
TPC-1, 8505C, KAT4, ARO and XTC-1, otherwise reported
to be derived from thyroid cancer. However, during the course
of this work, Schweppe et al. (2008) performed short tandem
repeat and single-nucleotide polymorphism analysis of several
thyroid cancer cell lines and suggested that cell lines ARO and
KAT4 may be derivates of the HT-29 colon cancer cell line.
Also, NPA was suggested to be a derivative of the M14/MDA-
MB-435S melanoma cell line.
The above-mentioned 10 cell lines were maintained in RPMI
medium, supplemented with 10% fetal bovine serum, 100 mg/
ml streptomycin and 100U/ml penicillin, in a humidified
atmosphere, with 5% CO2, at 37 1C. The cell line HEK293 was
maintained in Dulbecco’s modied Eagle’s medium with 10%
fetal bovine serum and 100 mg/ml penicillin/streptomycin.
HEK293 cells, used primarily for reporter assays, were
transfected by the calcium phosphate method. Transfection
of the remaining cell lines was achieved using Lipofectamin
Reagent (Invitrogen, Carlsbad, CA, USA).
Microarray global gene expression analysis
Tissue samples collected immediately after surgical resection
were directly put into TRIZOL (Ambion Inc., Austin, TX,
USA) and immediately homogenized. RNA was extracted
according to the TRIZOL protocol and further clean-up was
achieved by passing RNA through an RNeasy column
(Qiagen, Hilden, Germany). Complementary RNA was
synthesized by reverse transcriptase–PCR using an oligo dT
primer with a T7 promoter overhang followed by in vitro
transcription. Complementary RNA was labeled by incorpor-
ating biotinylated nucleotides. The complementary RNA
target was fragmented and hybridized to the HG U133 Plus
2.0 genechip (Affymetrix). After staining and image acquisition,
the signal intensity data were normalized by the invariant
probeset method and the expression values were computed using
the dChip software (Cheng Li Lab, http://biosun1.harvard.edu/
complab/dchip/).
mRNA expression
RNA was obtained from macrodissected 4 20 mm tissue
sections with the RecoverAll RNA Isolation Kit (Ambion).
RNA from cell lines was purified by the TRIZOL protocol.
After cDNA synthesis employing MMLV Reverse Transcrip-
tase (Applied Biosystems), TaqMan Gene Expression assay
hs-00218582_m1 was used to measure LRP1B expression,
matrix metalloproteinase 2 was assayed by TaqMan
hs00234422_m1 qRT–PCR experiments. A normal reference
was produced by pooling RNAs from nine samples of normal
thyroid tissue, treated in the same way as the tumor samples. Data
were analyzed by the absolute quantification method.
Validation series
A validation set of cases, gathered by an independent group,
consisted of 30 thyroid lesions (12 FTAs and 18 FTCs) and 12
specimens of normal thyroid tissue, which were indepen-
dently assessed for LRP1B expression by analyzing the data
concerning the LRP1B probesets represented in the GeneChip
Human Exon 1.0 ST Array (Affymetrix). Thyroid samples
were collected immediately after surgical resection, snapped
frozen and stored at 80 1C. All samples were visually
inspected on 5mm hematoxylin and eosin-stained frozen
sections by the pathologist (JC-T). Cryostat sections were
disrupted by using a Polytron homogeneizer (Glen Mills Inc.,
Clifton, NJ, USA) and total RNA was isolated from cryostat
sections using RNeasy Mini Kit (Qiagen) following the
manufacturer’s instructions. RNA quality was assessed on a
bioanalyser (Agilent Technologies) and samples with RIN
(RNA integrity number) 47.0 were used for array experi-
ments. In total, 1 mg of the total RNA was used for rRNA
reduction, synthesis, fragmentation and labeling following the
standard Affymetrix Whole-Transcript Sense Target-Labeling
Assay protocol. Each thyroid sample was hybridized with an
Affymetrix Human Exon 1.0 ST microarray. Background
correction, normalization, probe summarization and data
analysis were done with Partek Genomics Suite software
(Parket Incorporated, St Louis, MO, USA) using rate
monotonic algorithm.
LRP1B mutation analysis
We designed 91 sets of PCR primers, which resulted in the
amplification of flanking intronic boundaries and coding
sequences of the 91 exons of LRP1B. We also used a set of
11 exonic primer pairs in order to amplify cDNA fragments
ranging from 1 to 1.4 kbp encompassing several exons. PCR
products were directly sequenced. Primer sequences are
available upon request.
Copy number analysis
We used TaqMan Copy number assay (Applied Biosystems) in
order to estimate the copy number at several genomic locations
within LRP1B, namely at exons 5 (assay hs-02812600_cn), 44
(assay hs-02217633_cn) and 90 (assay hs-05832428_cn), and
also near the centromeric region of chromosome 2q (assay hs-
04631472_cn). A similar strategy was used to determine copy
number at the genomic location of miR-548a-3 (assays
hs-05036789_cn and hs-06224496_cn) and at proximity of the
8q centromere (assay hs-06217400_cn). Multiplex genomic
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qRT–PCR reactions, containing VIC-TaqMan-primer/probes
for an internal reference gene (RNAse P) and FAM-labeled
TaqMan-primer/probes for the interrogated location, were
performed in triplicates. Results were analyzed with the
CopyCaller software (Applied Biosystems). DNA copy number
was calibrated by using a blood sample run in the same plate.
DNA methylation analysis
Genomic DNA was converted by bisulfite treatment using the
Epitect modification kit (Qiagen) and subsequently subjected
to PCR amplification of two regions of the promoter: fragment
1 (131 to þ 100, from ATG) and fragment 2 (þ 217 to
þ 365). The bisulfite PCR products were directly sequenced.
Constructs and expression vectors
50CpG island reporter constructs. Two fragments of the LRP1B
CpG island, obtained by PCR amplification of nucleotides
429 to 1 from the ATG (fragment A) and of nucleotides þ 1
to þ 530 (fragment B), were ligated into the pTAL-LUC vector
(ClonTech, Mountain View, CA, USA), encoding the firefly
luciferase gene under a basic TATA-like promoter region of the
herpes simplex virus thymidine kinase promoter.
In vitro methylation using bacterial methyltransferases. Bac-
terial methyltransferases with distinct specificities, M.Sss-I,
M.Hpa-II and M.Msp-I (methylating at *CG, C*CGG and
*CCGG, respectively), were used to methylate the CpG island
constructs in vitro. Methylation reactions were set up by
incubating 2 mg of plasmid DNA with 10 units of methyl-
transferase, in the presence of S-adenosylmethionine, at 37 1C,
overnight. After in vitro methylation, reporters were char-
acterized by bisulfite sequencing.
30UTR reporter constructs. We inserted a 645-bp sequence of
the 30 untranslated region (30UTR) of LRP1B containing the
miRNA-548a-3 target site downstream of the firefly luciferase
reporter in the pMIR-Report vector (Ambion). By PCR, we
generated both wild-type and a mutant version of the 30UTR
in which two nucleotides from the target sequence comple-
mentary to the seed region of miRNA-548a-3 were mutated.
Expression vectors. A pCDNA3.0 vector expressing an
LRP1B mini-receptor (mLRP1B) comprised of the entire
cytoplasmatic tail, the trans-membrane region and extracel-
lular sub-domain IV, which mimics the function and traffick-
ing of LRP1B, was kindly provided by Dr Guojun Bu. An
expression vector encoding the pre-miR-548a-5p (pEP-mir-
548a-3) was purchased from Cell Biolabs (Cell Biolabs Inc.,
San Diego, CA, USA). A pCMV-b vector expressing the p300
histone-acetyltransferase was obtained from Dr William Sell-
ers, through Addgene (Addgene plasmid 10718).
Reporter assays. DNA mixtures consisted of 0.5mg expres-
sion plasmid, 0.5mg of the reporter plasmid, 0.5 mg of PDM2-
LacZ (expressing b-galactosidase) and pUC18, to complete
5mg total DNA. Cells were incubated with calcium phosphate–
DNA complexes for 24 h and cultured in fresh medium for an
additional 24–48 h. Cells were harvested and lysed in 150 ml of
reporter lysis buffer, and luciferase and b-galactosidase assays
were performed. The luciferase activity was normalized with
the corresponding b-Galactosidase activity (measures transfec-
tion efficiency). All conditions were performed in triplicates
and experiments were performed three times.
Proximity ligation assay. Analysis of the interaction between
DNA and p300 was performed by a proximity ligation assay as
described by Gustafsdottir et al. (2007), with the following
modifications:
(1) The variable region of the DNA probe was designed to
have 24 nucleotides encompassing the predicted p300 binding
site at LRP1B intron 1 in the wild-type (CCCCTCCGGG
AGTGTGTGCACTTG) and mutated (CCCCTCCGGGACA
GTGTGCACTTG) configurations, as well as with methylated
sites (CCCCTC*CGGGAGTGTGTGCACTTG and CCCCT*
CCGGGAGTGTGTGCACTTG, where ‘*C’ represents the
sites where a 5-methyl cytosine modification was introduced).
The variable part of the probes was made double-stranded by
hybridizing an equimolar amount of a complementary 24-mer
oligonucleotide in which the methylation sites were placed in
the symmetrical positions. Probes were synthesized at MWG
Eurofins (Eurofins MWG Operon, Ebersberg, Germany).
(2) Proximity ligation reactions were set up in a p300
binding buffer described by Rikitake and Moran (1992). Then,
a p300 biotinylated antibody (R&D Systems, Minneapolis,
MN, USA) conjugated with streptavidin-oligonucleotide
probes (kindly provided by Sigurn Gustafsdottir) was added
and the mixture was incubated for 4 h at 4 1C.
Treatment of cells with 5AZA and TSA. A total of 1 105
cells per well were seeded, in triplicates, in six-well-chambers.
The next day, cells were cultured in a medium containing either
regular medium, or medium supplemented with dimethyl
sulfoxide solvent or 5 uM 5AZA (Sigma-Aldrich, St Louis,
MO, USA). Medium corresponding to each formulation was
renewed daily for 4 days, after which nucleic acids were
extracted. Treatment with TSA alone was performed by
adding 100 nM of TSA to the medium for 16 h. For the
combination of 5AZA with TSA, 100 nM TSA (Sigma) was
added at the fourth day of the 5AZA treatment and kept for
16 h, after which the experiment was stopped.
Quantification of miRs. miRNAs were quantified using Taq-
Man MicroRNA Assays (Applied Biosystems). Starting from
10 ng of total RNA, primer-specific reverse transcription was
performed and 2 ml of cDNA was used in qRT–PCR to
quantify each miR. Expression values were normalized to the
levels of miRNA-U6b determined in the same RNA samples.
A pool of nine RNAs derived from normal thyroid tissue was
used as the normal reference. Data were analyzed using the
delta-delta-Ct method.
Soft agar assays. For soft agar assays, we prepared plates
containing a bottom layer of 0.7% agar in Dulbecco’s modied
Eagle’s medium, 10% fetal bovine serum, 1% penicillin/
streptomicin and 5000 cells were diluted in 2 Dulbecco’s
modied Eagle’s medium, 20% fetal bovine serum, 2%
penicillin/streptomycin P, mixed with equal volume of 1%
agar at 40 1C and plated on the agar plates. After 2–3 weeks,
wells were stained with crystal violet and colonies were
photographed and counted.
Chicken embryo in vivo growth assay. The chicken embryo
chorioallantoic membrane model has been used to assay
tumorigenicity as previously described (Hagedorn et al., 2005)
with minor modifications, which consisted of placement of a
nylon ring with 5mm diameter on top of the growing chicken
chorioallantoic membrane under sterile conditions for adding
2 106 per embryo.
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In vitro matrigel invasion assays. Matrigel Invasion Cham-
bers (BD Biosciences, Franklin Lakes, NJ, USA) were used to
assess the in vitro metastatic potential according to reported
procedures (Mateus et al., 2009).
Gelatin zymography. The level of gelatinases was deter-
mined as described by others (Ribeiro et al., 2010) in
24-h conditioned medium derived from 2.5 105 cells seeded
onto six-well plates previously coated with 20 mg/ml fibronec-
tin. The experiment was performed in triplicates (three wells
for each condition) and was repeated twice.
Statistical analyses
Differences between groups were tested by the Mann–Whitney
test. Correlations were assessed by the Pearson coefficient.
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